Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Brady

Showing results (581-590 of 605) with videos related to

Pageof 61
Sort By:
Blood|April 6, 2026
The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseasesCongyu Lu, Gavriel Y Matt, Robin Paul, et al.
Blood Cancer Discovery|July 12, 2021
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapySima Jeha, John Choi, Kathryn G Roberts, et al.
Nature Communications|October 15, 2020
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterationsSamuel W Brady, Yanling Liu, Xiaotu Ma, et al.
Science Advances|April 29, 2026
IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumorsKhadija Banu, Mohammad Aslam Khan, Sihan Li, et al.
Pediatrics|November 29, 2019
A National Approach to Pediatric Sepsis SurveillanceHeather E Hsu, Francisca Abanyie, Michael S D Agus, et al.
Nature Biomedical Engineering|April 25, 2019
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.
Nature Biomedical Engineering|March 29, 2019
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Leukemia|May 13, 2025
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemiaRuth W Wang'ondu, Emily Ashcraft, Ti-Cheng Chang, et al.
Nature Communications|January 29, 2025
Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemiaZhenhua Li, Huanbin Zhao, Wenjian Yang, et al.
Pageof 61

Showing results (581-590 of 605) with videos related to

Sort By:
Pageof 61
Blood|April 6, 2026
The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseasesCongyu Lu, Gavriel Y Matt, Robin Paul, et al.
Blood Cancer Discovery|July 12, 2021
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapySima Jeha, John Choi, Kathryn G Roberts, et al.
Nature Communications|October 15, 2020
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterationsSamuel W Brady, Yanling Liu, Xiaotu Ma, et al.
Science Advances|April 29, 2026
IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumorsKhadija Banu, Mohammad Aslam Khan, Sihan Li, et al.
Pediatrics|November 29, 2019
A National Approach to Pediatric Sepsis SurveillanceHeather E Hsu, Francisca Abanyie, Michael S D Agus, et al.
Nature Biomedical Engineering|April 25, 2019
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.
Nature Biomedical Engineering|March 29, 2019
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Leukemia|May 13, 2025
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemiaRuth W Wang'ondu, Emily Ashcraft, Ti-Cheng Chang, et al.
Nature Communications|January 29, 2025
Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemiaZhenhua Li, Huanbin Zhao, Wenjian Yang, et al.
Pageof 61